Source abstract
Abstract
Theranostic photonic nanoparticles (TPNs) that cross the blood–brain barrier (BBB) and efficiently deliver a therapeutic agent to treat brain diseases, simultaneously providing optical tracking of drug delivery and release, are introduced. These TPNs are constructed by physical encapsulation of visible and/or near‐infrared photonic molecules, in an ultrasmall micellar structure (<15 nm). Phytochemical curcumin is employed as a therapeutic as well as visible‐emitting photonic component. In vitro BBB model studies and animal imaging, as well as ex vivo examination, reveal that these TPNs are capable of transmigration across the BBB and subsequent accumulation near the orthotopic xenograft of glioblastoma multiforme (GBM) that is the most common and aggressive brain tumor whose vasculature retains permeability‐resistant properties. The intracranial delivery and release of curcumin can be visualized by imaging fluorescence produced by energy transfer from curcumin as the donor to the near‐infrared emitting dye, coloaded in TPN, where curcumin induced apoptosis of glioma cells. At an extremely low dose of TPN, a significant therapeutic outcome against GBM is demonstrated noninvasively by bioluminescence monitoring of time‐lapse proliferation of luciferase‐expressing U‐87 MG human GBM in the brain. This approach of TPN can be generally applied to a broad range of brain diseases.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Barrier Structure and Function Studies · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Theragnosis and Center for Neuro‐Medicine Korea Institute of Science and Technology (KIST) Seoul 136‐791 South Korea
Institute for Lasers Photonics and Biophotonics Department of Chemistry State University of New York Buffalo NY 14260 USA
Department of Organic and Nano System Engineering Konkuk University Seoul 143‐701 South Korea
Department of Medicine Division of Allergy, Immunology, and Rheumatology State University of New York Clinical Translational Research Center Buffalo NY 14203 USA
Funding
National Research Foundation of Korea · Korea Health Industry Development Institute · National Institutes of Health
References (24)
Show source-provided references
3. Nersesyan H. · Ther. Clin. Risk Manage. · 2007 · 3 · 381
9. Chandana S. R. · Am. Fam. Physician · 2008 · 77 · 1423